-
Autor
Bathija, Sacheeta 1 Cai, Qian 1 Gregora, Evzen 1 Gros, Blanca 1 Heindorfer, Adriana 1 Jelinek, Tomas 1 Jungova, Alexandra 1 Kessler, Petr 1 Kunovszki, Peter 1 Lam, Annette 1 Maisnar, Vladimir 1 Minarik, Jiri 1 Obernauerova, Jarmila 1 Pavlicek, Petr 1 Popkova, Tereza 1 Pospisilova, Lenka 1 Sandecka, Viera 1 Spicka, Ivan 1 Stejskal, Lukas 1 Stork, Martin 1
-
Pracoviště
Charles University Hospital and Facul... 1 Charles University and General Hospit... 1 Hospital Ceske Budejovice Ceske Budej... 1 Hospital Novy Jicin Novy Jicin Czech ... 1 Hospital Pelhrimov Pelhrimov Czech Re... 1 Institute of Biostatistics and Analys... 1 Janssen Cilag GmbH Neuss Germany 1 Janssen Cilag Madrid Spain 1 Janssen Global Services Budapest Hungary 1 Janssen Global Services Raritan NJ USA 1 Janssen Global Services Titusville NJ... 1 KZ Masaryk Hospital in Usti nad Labem... 1 Liberec Regional Hospital Liberec Cze... 1 Motol University Hospital Prague Czec... 1 Regional Hospital Mlada Boleslav Mlad... 1 Silesian Hospital in Opava Opava Czec... 1 University Hospital Brno Brno Czech R... 1 University Hospital Kralovske Vinohra... 1 University Hospital Olomouc Olomouc C... 1 University Hospital Ostrava and Facul... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Zeměpisné označení
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
-
Autor
Bathija, Sacheeta 1 Cai, Qian 1 Gregora, Evzen 1 Gros, Blanca 1 Heindorfer, Adriana 1 Jelinek, Tomas 1 Jungova, Alexandra 1 Kessler, Petr 1 Kunovszki, Peter 1 Lam, Annette 1 Maisnar, Vladimir 1 Minarik, Jiri 1 Obernauerova, Jarmila 1 Pavlicek, Petr 1 Popkova, Tereza 1 Pospisilova, Lenka 1 Sandecka, Viera 1 Spicka, Ivan 1 Stejskal, Lukas 1 Stork, Martin 1
-
Pracoviště
Charles University Hospital and Facul... 1 Charles University and General Hospit... 1 Hospital Ceske Budejovice Ceske Budej... 1 Hospital Novy Jicin Novy Jicin Czech ... 1 Hospital Pelhrimov Pelhrimov Czech Re... 1 Institute of Biostatistics and Analys... 1 Janssen Cilag GmbH Neuss Germany 1 Janssen Cilag Madrid Spain 1 Janssen Global Services Budapest Hungary 1 Janssen Global Services Raritan NJ USA 1 Janssen Global Services Titusville NJ... 1 KZ Masaryk Hospital in Usti nad Labem... 1 Liberec Regional Hospital Liberec Cze... 1 Motol University Hospital Prague Czec... 1 Regional Hospital Mlada Boleslav Mlad... 1 Silesian Hospital in Opava Opava Czec... 1 University Hospital Brno Brno Czech R... 1 University Hospital Kralovske Vinohra... 1 University Hospital Olomouc Olomouc C... 1 University Hospital Ostrava and Facul... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Zeměpisné označení
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
Free Medical Journals od 2011
Freely Accessible Science Journals od 2011-01-28
Nature Open Access od 2011-01-01
PubMed Central od 2011
Europe PubMed Central od 2011
ProQuest Central od 2011-01-01
Open Access Digital Library od 2011-01-01
Open Access Digital Library od 2011-01-01
Health & Medicine (ProQuest) od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources od 2010
PubMed
37752128
DOI
10.1038/s41408-023-00906-7
Knihovny.cz E-zdroje
Smoldering multiple myeloma (SMM) is an asymptomatic precursor to active multiple myeloma (MM). The aim of this study was to report clinical characteristics and outcomes of patients with SMM stratified based on their risk of progression to MM using the Mayo 20/2/20 criteria. Data were leveraged from the Czech Myeloma Group Registry of Monoclonal Gammopathies (RMG). Key outcomes included progression-free survival from SMM diagnosis to active MM diagnosis or death (PFS), progression-free survival from SMM diagnosis to progression on first line (1 L) MM treatment or death (PFS2), and overall survival (OS). Of 498 patients, 174 (34.9%) were classified as high risk and 324 (65.1%) as non-high risk. Median follow-up was approximately 65 months. During follow-up, more patients in the high-risk vs non-high-risk group received 1 L MM treatment (76.4% vs 46.6%, p < 0.001). PFS, PFS2, and OS were significantly shorter in high-risk vs non-high-risk patients (13.2 vs 56.6 months, p < 0.001; 49.9 vs 84.9 months, p < 0.001; 93.2 vs 131.1 months, p = 0.012, respectively). The results of this study add to the growing body of evidence that patients with high-risk vs non-high-risk SMM have significantly worse outcomes, including OS.
- MeSH
- doba přežití bez progrese choroby MeSH
- doutnající mnohočetný myelom * diagnóza epidemiologie terapie MeSH
- lidé MeSH
- mnohočetný myelom * diagnóza epidemiologie terapie MeSH
- registrace MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
Sdílet
Název dokumentu
Po ukončení testovacího provozu bude odkaz přesměrován adresu produkční verze portálu Medvik.